Condition: Mucopolysaccharidosis Type II · Metabolic Diseases · Sponsor: AO GENERIUM
This is phase 2/3 study to evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy of the investigational product GNR-055 in MPS II (Hunter syndrome) patients of different age groups.
This description comes directly from the study's public registry record.
Svetlana B. Korotkova, MD, PhD · +7(495) 988 47 94 · sbkorotkova@generium.ru
Oksana A. Markova, MD, MSc · +7(495) 988 47 94 · oamarkova@generium.ru
Always discuss trial participation with your own doctor first.
| Federal State-Funded Healthcare Institution Central Clinical Hospital of the Russian Academy of Sciences (Research Institute of Pediatrics and Child Health Protection of the Central Clinical Hospital of the Russian Academy of Sciences) | Moscow, Russia | Not Yet Recruiting |
| Federal State Budgetary Educational Institution of Higher Education "St. Petersburg State Pediatric Medical University" of the Ministry of Health of the Russian Federation | Saint Petersburg, Russia | Not Yet Recruiting |
| V.I. Vernadsky Crimean Federal University | Simferopol, Russia | Recruiting |
| State Budgetary Healthcare Institution Republican Medical Genetic Center | Ufa, Russia | Recruiting |
| State Autonomous Healthcare Institution of the Sverdlovsk Region Regional Children's Clinical Hospital | Yekaterinburg, Russia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05208281